SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 130615.
  • 2
    Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, Tannenbaum C, Wein AJ. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009; 19: 38094.
  • 3
    Toviaz (Fesoterodine Fumarate). Full prescribing information. New York, NY: Pfizer Inc., 2010.
  • 4
    European Medicines Agency (EMEA). EPARs for authorized medicinal products for human use. European Public Assessment Report for Toviaz (Product Information). Updated August 2009. Available at http://www.emea.europa.eu/humandocs/Humans/EPAR/toviaz/toviaz.htm. (last accessed 20 October 2009).
  • 5
    Ellsworth P. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag 2009; 5: 86976.
  • 6
    Cawello W, Auer S, Hammes W, Sachse R, Horstmann R. Multiple dose pharmacokinetics of fesoterodine in human subjects. Arch Pharmacol 2002; 365 (Suppl. 1): R110.
  • 7
    Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9: 178796.
  • 8
    Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future 2004; 29: 71520.
  • 9
    Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 2008; 102: 11339.
  • 10
    Kottkamp H, Hindricks G, Breithardt G. Role of anticoagulant therapy in atrial fibrillation. J Cardiovasc Electrophysiol 1998; 9: (8 Suppl.): S8696.
  • 11
    Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 6774.
  • 12
    Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: (1 Suppl.): 8S21S.
  • 13
    Stirling Y, Howarth DJ, Stockley R, Bland R, Towler CM, Harding SM. Comparison of the bioavailabilities and anticoagulant activities of two warfarin formulations. Br J Haematol 1982; 51: 3746.
  • 14
    Lilja JJ, Backman JT, Neuvonen PJ. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam – probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther 2007; 81: 8339.
  • 15
    Alexander SPH, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 2009; 158 (Suppl. 1): S1S254.